Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

BioNTech reports strong first half, expects demand to grow

BioNTech, which teamed with Pfizer to develop the first widely used COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year

The Independent UK

Republicans condemned for striking down insulin cap in major Biden legislation: ‘Shame on you’

‘How many people have to die from insulin rationing before they stop blocking action?’

The Independent UK

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

East Bristol has lost most pharmacies in England since 2016

And there are concerns that more pharmacies could close soon

Bristol Post

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Reuters

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

Fears of 'chemist deserts' in areas where a third of pharmacies have shut in six years

New data reveals Bristol East, Bradford West, Pendle, Torbay and Hove are among the areas to have lost the largest numbers of pharmacies in the last few years

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

COVID-19 vaccine sales push Moderna past expectations in Q2

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts

The Independent UK

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

US allows pharmacists to prescribe Pfizer's COVID pill

U.S. pharmacists can now prescribe the leading COVID-19 pill directly to patients

The Independent UK

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Daily Record

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Reuters

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

The Independent UK

Tentative $161.5 million settlement reached in opioid trial

Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement

Benzinga

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

StockNews.com

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Axios

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

StockNews.com

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

AAP

CSL profit falls due to pandemic curbs

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

1 … 139 140 141 142

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.